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We retrospectively reviewed patients who were treated with an indwelling ureteral stent to manage
extrinsic ureteral obstruction due to advanced gynecological and gastrointestinal cancers. A total of 34
patients, including 17 with gynecological cancer and 17 with gastrointestinal cancer, underwent a successful
initial ureteral stent placement from January 2007 to December 2011. Functional ureteral stent failures,
which required percutaneous nephrostomy within 3 months after initial ureteral stenting, occurred in 14 of
the 34 patients (41%) during follow-up. The risk factors of functional ureteral stent failure were bilateral
ureteral obstruction, elevated serum creatinine level, poor performance status, subsequent therapy for
primary cancer after ureteral stent placement, presence of peritonitis carcinomatosa, and gastrointestinal
cancer. Patients with gastrointestinal cancer had a higher rate of stent failure than did those with
gynecological cancer (p＝0.01). Median survival from the diagnosis of hydronephrosis for patients with
gastrointestinal and gynecological cancers was 9 and 23 months, respectively (p＝ 0. 02). Retrograde
ureteral stenting is a useful treatment for malignant ureteral obstruction. However, patients with
gastrointestinal cancer had a high stent failure rate and a short survival time from the diagnosis of
hydronephrosis. Indications for retrograde ureteral stenting for malignant ureteral obstruction should be
carefully considered while taking into account stent failure risk, patient prognosis and quality of life.
(Hinyokika Kiyo 60 : 13-16, 2014)






























テントは太さ 6 Fr，側孔ありのダブル J カテーテル
で，材質は2010年まではポリウレタン，2010年以後は
主にシリコーンを用いた．原則として尿管ステントは








症例をステント無効 (early stent failure) と定義した．
尿管ステントの効果と臨床因子，原因疾患との関連に
ついて，統計学的に検討した．統計学的処理にはカイ
2乗検定および Student t 検定を用いた．
結 果

















Table 1. Patients characteristics
Characteristics n
Age, years









Preoperative serum creatinine, mg/dl










failure (n＝11) P value
Age, years
Median (range) 64 (46-82) 58 (36-76) 0.76
Sex
Male 4 3 0.87
Female 19 8
Performance status
0-1 20 4 0.005
2 3 7
Hydronephrosis
Bilateral 3 9 0.0002
Unilateral 20 2
Serum creatinine, mg/dl
Median (range) 0.9 (0.5-6.3) 2.8 (0.7-10.8) 0.003
Subsequent therapy
Yes 19 5 0.04
No 4 6
Peritonitis carcinomatosa




cancer 15 2 0.01
Gastrointestinal
cancer 8 9





cancer (n＝17) P value
Age, years
Median (range) 58 (44-82) 66 (36-76) 0.3
Sex
Male 0 7 ―
Female 17 10
Performance status
0-1 14 11 0.21
2 3 6
Hydronephrosis
Bilateral 5 7 0.36
Unilateral 12 10
Serum creatinine, mg/dl
Median (range) 0.9 (0.5-10.8) 1.1 (0.6-4.4) 0.31
Stent placement period, month
Median (range) 13 (2-48) 3 (0-24) 0.003
Survival time, month
















































life : QOL) の低下となる危険性もあり，水腎症に対す
る尿管ステントの適応に関しては慎重を要する．













































1) 五十嵐 学，高橋 聡，田中俊明，ほか : 進行癌
による上部尿路閉塞症例に対する尿管ステント留
置の意義．臨泌 62 : 149-154，2010
2) Izumi K, Mizokami A, Maeda Y, et al. : Current
Outcome of patients with ureteral stents for the
management of malignant ureteral obstruction. J
竹原，ほか : 尿管閉塞・尿管ステント留置術 15
Urol 185 : 556-561, 2011
3) Kamiyama Y, Matsuura S, Kato M, et al. : Stent
failure in the management of malignant extrinsic
ureteral obstruction : risk factors. Int J Urol 18 : 379-
382, 2011
4) Rosevear HM, Kim SP, Wenzler DL, et al. : Retro-
grade ureteral stents for extrinsic ureteral obstruction :
nine years’experience at University of Michigan.
Urology 70 : 846-850, 2007
5) Ganatra AM and Loughlin KR : The management of
malignant ureteral obstruction treated with ureteral
stents. J Urol 174 : 2125-2128, 2005
6) Wong LM, Cleeve LK, Milner AD, et al. : Malignant
ureteral obstruction outcomes after intervention : have
things changed ? J Urol 178 : 178-183, 2007
7) Hyams ES and Shah O : Malignant extrinsic ureteral
obstruction : a survey of urologists and medical oncolo-
gists regarding treatment patterns and preferences.
Urology 72 : 51-56, 2008
8) Ku JH, Lee SW, Jeon HG, et al. : Percutaneous
nephrostomy versus indwelling ureteral stents in the
management of extrinsic ureteral obstruction in ad-
vanced malignancies : are there differences. Urology
64 : 895-899, 2004
9) Chung SY, Stein RJ, Landsittel D, et al. : 15-year
experience with the management of extrinsic ureteral
obstruction with indwelling ureteral stents. J Urol
172 : 592-595, 2004
10) Ishioka J, Kageyama Y, Inoue M, et al. : Prognostic
model for predicting survival after palliative urinary
diversion for ureteral obstruction : analysis of 140
cases. J Urol 180 : 618-621, 2008
11) Shenkarriz B, Shenkarriz H, Upadhyay J, et al. : Out-
come of palliative urinary diversion in the treatment of
advanced malignancies. Cancer 85 : 998-1003, 1999
12) 加藤成一，増栄孝子，増栄成泰，ほか : 長期留置
尿管ステントの患者背景調査とステント抜去の試
み．Jpn J Endourol 25 : 112-117, 2012
13) Jeong IG, Han SK, Joung Y, et al. : The outcome with
ureteric stents for managing non-urological malignant
ureteric obstruction. BJU Int 100 : 1288-1291, 2007
(Accepted on September 27, 2013)
Received on June 25, 2013
泌尿紀要 60巻 1号 2014年16
